PRNewswire-PRWeb | May 5, 2026
2026 DDW Oral Presentation: HepQuant DuO® Disease Severity Index (DSI) Outperforms Child-Pugh and MELD Scores in Predicting Risk of Esophageal Varices
Chicago, IL – May 5, 2026 – HepQuant, a leader in developing noninvasive, blood-based, quantitative testing to assess liver health, is excited to announce an oral presentation at Digestive Disease Week (DDW) 2026. Dr. Mitchell Shiffman1 will present data findings and discuss HepQuant DuO® as part of the DDW session:…
PRNewswire-PRWeb January 12, 2026
2026 MASH-TAG Oral Presentation: HepQuant DuO® Reveals Functional and Physiological Heterogeneity to Support Enhanced Clinical Trial Design
“HepQuant DuO is the ideal noninvasive test of liver health with clinical validation data confirming effective characterization of disease severity, tracking of disease progression and treatment impact.”, stated Dr. Gregory T. Everson, Chief Executive Officer of HepQuant. “HepQuant is committed to bringing this important quantitative tool to healthcare providers to transform liver health and improve patient management.”
PRNewswire-PRWebNovember 6, 2025
HepQuant Presents Exciting Abstracts at The Liver Meeting 2025 Demonstrating HepQuant DuO® Utility to Uncover Functional and Physiological Heterogeneity
HepQuant, a leader in developing noninvasive, blood-based, quantitative testing to assess liver health, will present three exciting abstracts demonstrating HepQuant DuO utility at The Liver Meeting 2025® conference this week. Each demonstrates how HepQuant DuO test results uncover functional and physiological heterogeneity in patients with advanced MASH and chronic HCV (Child Pugh A5 compared to Child Pugh A6). The third abstract presentation utilizes the HepQuant DuO test to measure the recovery of function in living donors who underwent right lobectomy.
PRNewswire-PRWeb October 14, 2025
HepQuant Announces Exciting New Data Utilizing HepQuant DuO® testing: Early Assessment of Resmetirom Treatment Benefit in Patients with Compensated MASH Cirrhosis
HepQuant, a leader in developing noninvasive, blood-based, quantitative testing to assess liver health, announces promising findings from a study utilizing the HepQuant DuO test to evaluate the impact of resmetirom treatment in patients with metabolic dysfunction-associated steatohepatitis (MASH)-related Child-Pugh A cirrhosis. In the peer-reviewed publication, 83% of patients showed either stability or improvement in liver function, as measured by DSI, after 48 weeks.In The News
Dr. Greg Everson Speaks at PSC Forum 9 in Washington, DC
Dr. Greg T. Everson presented at the annual PSC Forum 9 in Washington, DC, sharing how the oral cholate challenge test can help clinicians more accurately assess disease severity in patients with primary sclerosing cholangitis (PSC). Click here to see his presentation.
September 10, 2025
HepQuant DuO™ Estimates Risk for Clinical Outcome and Quantifies Changes in Risk
Dr. Greg Everson just shared groundbreaking insights at the Liver Forum in Paris! His presentation highlights how HepQuant DuO™ helps estimate clinical risk and track changes over time — a major step forward in liver disease management. [View his presentation here.]
Events
June 11, 2026 - June 11, 2026Denver, CO